Christine Y. Malati

Christine Y. Malati

Auto-generated profile, based on publicly available information

Christine Y. Malati

United States Agency for International Development Washington DC USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2023 in Journal of the International AIDS Society
Verified
Journal Article
Open access
DCDelivette Castor
Delivette Castor
CHCraig J. Heck
Craig J. Heck
DQDaniela Quigee
Daniela Quigee
NTNiharika Vasant Telrandhe
Niharika Vasant Telrandhe
KKKiran Kui
Kiran Kui
SFSteven Forsythe
Steven Forsythe
Introduction: Several low‐ and middle‐income countries (LMICs) are preparing to introduce long‐acting pre‐exposure prophylaxis (LAP). Amid multiple pre‐exposure prophylaxis (PrEP) options and constrained funding, decision‐makers could benefit from systematic implementation planning and aligned costs. We reviewed national costed implementation plans (CIPs) to describe relevant implementation inputs and activities (domains) for informing the costed rollout of LAP. We assessed how primary costing evidence aligned with those domains.Methods: We conducted a rapid review of CIPs for oral PrEP and family planning (FP) to develop a consensus of implementation domains, and a scoping review across nine electronic databases for publications on PrEP costing in LMICs between January 2010 and June 2022. We extracted cost data and assessed alignment with the implementation domains and the Global Health Costing Consortium principles.Results: We identified 15 implementation domains from four national PrEP plans and FP‐CIP template; only six were in all sources. We included 66 full‐text manuscripts, 10 reported LAP, 13 (20%) were primary cost studies‐representing seven countries, and none of the 13 included LAP. The 13 primary cost studies included PrEP commodities (n = 12), human resources (n = 11), indirect costs (n = 11), other commodities (n = 10), demand creation (n = 9) and counselling (n = 9). Few studies costed integration into non‐HIV services (n = 5), above site costs (n = 3), supply chains and logistics (n = 3) or policy and planning (n = 2), and none included the costs of target setting, health information system adaptations or implementation research. Cost units and outcomes were variable (e.g. average per person‐year).Discussion: LAP planning will require updating HIV prevention policies, technical assistance for logistical and clinical support, expanding beyond HIV platforms, setting PrEP achievement targets overall and disaggregated by method, extensive supply chain and logistics planning and support, as well as updating health information systems to monitor multiple PrEP methods with different visit schedules. The 15 implementation domains were variable in reviewed studies. PrEP primary cost and budget data are necessary for new product introduction and should match implementation plans with financing.Conclusions: As PrEP services expand to include LAP, decision‐makers need a framework, tools and a process to support countries in planning the systematic rollout and costing for LAP.

15 April 2019 in Journal of the International AIDS Society
Verified
Journal Article
Open access
PDF file
CMChristine Y Malati
Christine Y Malati
RGRachel Golin
Rachel Golin
LOLisa O'BRien
Lisa O'BRien
NSNandita Sugandhi
Nandita Sugandhi
MSMeena Srivastava
Meena Srivastava
BPBenjamin R Phelps
Benjamin R Phelps
Introduction: Despite a significant reduction in mother‐to‐child transmission of HIV, an estimated 180,000 children were infected with HIV in 2017, and only 52% of children under 15 years of age living with HIV (CLHIV) are on life‐saving antiretroviral therapy (ART). Without effective treatment, half of CLHIV die before the age of two years and only one in five survives to five years of age.Discussion: Over the past four years, the United States Food and Drug Administration tentatively approved new formulations of lopinavir/ritonavir (LPV/r) in the form of oral pellets and oral granules. However, the slow uptake of the aforementioned formulations in the low‐ and middle‐income countries with the highest paediatric HIV burden is largely due to three challenges: limited manufacturing capacity; current unit cost of the pellets and granules; and slow uptake of these new formulations by policy makers and health care workers.Conclusions: Solutions to overcome these barriers include ensuring availability of an adequate supply of LPV/r oral pellets and oral granules, considering all programmatic and clinical factors when selecting paediatric ART formulations, and leveraging current resources to decrease paediatric HIV morbidity and mortality.

7 November 2022 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Open access
RKRakhi Karwa
Rakhi Karwa
ESEllen Schellhase
Ellen Schellhase
CMChristine Y. Malati
Christine Y. Malati
SPSonak D. Pastakia
Sonak D. Pastakia
IMImran Manji
Imran Manji
MMMonica Miller
Monica Miller
Health disparities exist globally in high‐income and low‐ and middle‐income countries. They are driven by social determinants of health (SDOH). While a role for pharmacists in addressing SDOH exists, a lack of structured postgraduate training limits pharmacists from being equipped to build innovative programs and contribute to health policy on SDOH in an impactful way. Postgraduate training, specifically, fellowships provides opportunities for pharmacists to develop the needed skills for working with SDOH. The Purdue University College of Pharmacy (PUCOP)‐United States Agency for International Development (USAID) Global Health Equity Fellowship was developed to meet this training need. This 2‐y fellowship represents a partnership between USAID and PUCOP. During the fellowship, time is split between USAID in Washington DC, PUCOP in Indianapolis, Indiana, and the Purdue Kenya Partnership (PKP) in Eldoret, Kenya. The fellowship was developed with a foundation of core values, the creation of a logic model, strategic partnerships, maintaining an adaptable structure, and intentional partner communication. Fellow outcomes were evaluated in three categories: engagement, education, and scholarship. Fellows completed 10 experiential opportunities between three sites and participated in the development of new and supported ongoing care programs and policy implementation in both local and international settings. Fellows completed the following educational outcomes: completed an online Master of Public Health (MPH) through Purdue Global, provided 13 educational presentations and lectures at various sites, and precepted a total of 12 PUCOP advanced pharmacy practice experience (APPE) students and 16 Kenyan pharmacy interns and Master of Pharmacy (MPharm) students. Fellows completed three publications and two abstracts at international conferences. This established training model provides pharmacists with a structured path to gain the knowledge, skills, and attitudes to be leaders in addressing Global Health Equity.